Hartmut Goldschmidt

AI-based automated body composition analysis from whole-body MRI and (PET-) CT: an intermodal comparison from same-day examinations

Abstract Background To determine intermodal agreement of AI-derived volumetric body composition metrics between [18 F]FDG-PET/CT-derived low-dose CT and whole-body MRI (wb-MRI). Methods We retrospectively analyzed same-day whole-body low-dose CT, obtained from [ 18 F]FDG-PET/CT,...

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

Abstract In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in tran...

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report...